A Prospective Trial Comparing Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) and Conventional Open Thyroidectomy
Launched by TSEUNG KWAN O HOSPITAL, HONG KONG · Jan 25, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new surgical method called Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) to see if it is a safe and effective option for removing thyroid nodules, which are lumps in the thyroid gland. The trial compares this less invasive technique to the traditional open thyroid surgery, looking at how well patients recover, their satisfaction with the procedure, and any effects on their voice and swallowing.
To participate in this study, you should be between 65 and 74 years old and have a thyroid nodule that is either benign (non-cancerous) and smaller than 4 cm or a suspicious nodule that is less than 2 cm. Certain health conditions or previous surgeries may exclude you from participating. If you join, you can expect to undergo the TOETVA procedure and share your recovery experience, which will help researchers understand the benefits and challenges of this new approach. The trial is currently recruiting participants, and it aims to improve surgical options for patients with thyroid issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Benign thyroid nodule less than 4cm
- • Suspicious malignant thyroid nodule less than 2cm, suitable for transoral endoscopic surgery
- Exclusion Criteria:
- • Patients under 18 years old
- • Contraindication to general anaesthesia
- • Vulnerable population (e.g. Cognitive impairment, pregnant)
- • Previous anterior neck surgery
- • Previous radiotherapy at the head and neck region
- • Malignant thyroid nodule \> 2cm
- • Presence of another malignancy, lateral neck, or distant metastasis
- • Retrosternal goitre
- • Cervical spine disease precluding extension of the neck
- • Obesity with BMI \> 35kg/m2
- • Severe concomitant illness that drastically shortens life expectancy or increases risk of therapeutic intervention
- • Untreated active infection
- • Non-correctable coagulopathy
- • Emergency surgery
About Tseung Kwan O Hospital, Hong Kong
Tseung Kwan O Hospital, located in Hong Kong, is a leading healthcare institution dedicated to providing comprehensive medical services and advancing clinical research. As a prominent clinical trial sponsor, the hospital emphasizes innovative healthcare solutions and strives to enhance patient outcomes through rigorous scientific investigation. With a multidisciplinary approach and a commitment to ethical standards, Tseung Kwan O Hospital actively engages in various clinical trials to explore new therapies and treatment modalities, contributing to the global medical community while ensuring the highest level of patient care and safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Jason YK Chan
Study Director
Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong
Zenon Yeung
Principal Investigator
Department of Otorhinolaryngology, Head and Neck Surgery, The Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported